SDC1 and plasma cell myeloma: The antitumor action of chemically modified heparins has been shown to inhibit myeloma growth and angiogenesis via disruption of the heparanase/syndecan-1 axis (37), and our data strongly confirm the usefulness of this therapeutic approach.